C-3 Epimers Can Account for a Significant Proportion of Total Circulating 25-hydroxyvitamin D in Infants, Complicating Accurate Measurement and Interpretation of Vitamin D Status

CONTEXT We have recently introduced liquid chromatography-tandem mass spectrometry (LC-MS/MS) for 25-hydroxyvitamin D(2) (25OHD(2)) and 25OHD(3) testing. During subsequent clinical use, we identified significantly elevated results in some infants. We hypothesized this might represent assay interference caused by C-3 epimers of 25OHD(2) or 25OHD(3). OBJECTIVE Our aims were to 1) determine the prevalence of C-3 epimers of 25OHD(2) or 25OHD(3) in human serum, and 2) identify the patient populations that might be affected. STUDY DESIGN We modified our LC-MS/MS method to allow detection of C-3 epimers. We retested specimens from four patient groups with the new method and an extracted RIA: 1) children less than 1 yr old, 2) children 1-18 yr old, 3) adults aged 20-87 yr with liver disease, and 4) adults aged 19-91 yr without liver disease. RESULTS In 172 children from group 1 with detectable 25OHD(2) or 25OHD(3), we identified C-3 epimers in 39 (22.7%). The epimers contributed 8.7-61.1% of the total 25-OHD. There was an inverse relationship between patient age and epimer percentage (r = 0.48; P < 0.002). The RIA gave accurate 25-OHD results that correlated with the modified LC-MS/MS method. No C-3 epimers were detected in any of the other groups. CONCLUSIONS Significant concentrations of C-3 epimers of 25OHD(2) or 25OHD(3) are commonly found in infants. This can lead to overestimation of 25-OHD levels. Measurements in children less than 1 yr should therefore be performed with an assay that allows accurate detection of 25-OHD in the presence of its C-3 epimers.

[1]  K. Inouye,et al.  Measurement and characterization of C-3 epimerization activity toward vitamin D3. , 2005, Archives of biochemistry and biophysics.

[2]  R. St-Arnaud,et al.  The 3-epi- and 24-oxo-derivatives of 1α,25 dihydroxyvitamin D3 stimulate transcription through the vitamin D receptor , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  B. Hollis.  Editorial: The determination of circulating 25-hydroxyvitamin D: no easy task. , 2004, The Journal of clinical endocrinology and metabolism.

[4]  Alex J. Brown,et al.  Isolation and identification of 1α‐hydroxy‐3‐epi‐vitamin D3, a potent suppressor of parathyroid hormone secretion , 2005, Journal of cellular biochemistry.

[5]  J. Zerwekh.  The measurement of vitamin D: analytical aspects , 2004, Annals of clinical biochemistry.

[6]  P. Lips,et al.  Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. , 2001, Endocrine reviews.

[7]  C. Carlberg.  Molecular basis of the selective activity of vitamin D analogues , 2003, Journal of cellular biochemistry.

[8]  M. Uskoković,et al.  Production of 1alpha,25-dihydroxy-3-epi-vitamin D3 in two rat osteosarcoma cell lines (UMR 106 and ROS 17/2.8): existence of the C-3 epimerization pathway in ROS 17/2.8 cells in which the C-24 oxidation pathway is not expressed. , 1999, Bone.

[9]  E. Slatopolsky,et al.  1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. , 1999, Journal of cellular biochemistry.

[10]  A. Zittermann.  Vitamin D in preventive medicine: are we ignoring the evidence? , 2003, The British journal of nutrition.

[11]  M. Uskoković,et al.  Metabolites and analogs of 1α,25-dihydroxyvitamin D3: evaluation of actions in bone , 2001, Steroids.

[12]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[13]  B. Hollis,et al.  Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer. , 1993, Clinical chemistry.

[14]  T. Clemens,et al.  Serum vitamin D2 and vitamin D3 metabolite concentrations and absorption of vitamin D2 in elderly subjects. , 1986, The Journal of clinical endocrinology and metabolism.

[15]  D. Beitz,et al.  A sensitive competitive protein binding assay for vitamin D in plasma , 1981, Steroids.

[16]  T. Sakaki,et al.  Cell specificity and properties of the C-3 epimerization of Vitamin D3 metabolites , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[17]  R. Wood,et al.  1α,25-(OH)2-Vitamin D3Analogs with Minimalin VivoCalcemic Activity Can Stimulate Significant Transepithelial Calcium Transport and mRNA Expressionin Vitro☆☆☆ , 1996 .

[18]  M. Drezner,et al.  Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. , 2004, The Journal of clinical endocrinology and metabolism.

[19]  B. Boucher,et al.  Intestinal cholecalciferol absorption in the elderly and in younger adults. , 1978, Clinical science and molecular medicine.

[20]  H. Cross,et al.  Differentiation-Related Pathways of 1α,25-Dihydroxycholecalciferol Metabolism in Human Colon Adenocarcinoma-Derived Caco-2 Cells: Production of 1α,25-Dihydroxy-3epi-cholecalciferol , 1998 .

[21]  M. Uskoković,et al.  1α,25‐Dihydroxy‐3‐epi‐vitamin D3: In vivo metabolite of 1α,25‐dihydroxyvitamin D3 in rats , 1999 .

[22]  K. Inouye,et al.  C-3 Epimerization of Vitamin D3 Metabolites and Further Metabolism of C-3 Epimers , 2004, Journal of Biological Chemistry.

[23]  E. Gunter,et al.  Measurement of Vitamin D metabolites: an international perspective on methodology and clinical interpretation , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  P. Galan,et al.  Prevalence of Vitamin D Insufficiency in an Adult Normal Population , 1997, Osteoporosis International.

[25]  Kathleen M. Fairfield,et al.  Vitamins for chronic disease prevention in adults: scientific review. , 2002, JAMA.

[26]  B. Hollis,et al.  Improved radioimmunoassay for vitamin D and its use in assessing vitamin D status. , 1985, Clinical chemistry.

[27]  W. Okamura,et al.  Metabolism of 1α,25-dihydroxyvitamin D3 and its C-3 epimer 1α,25-dihydroxy-3-epi-vitamin D3 in neonatal human keratinocytes , 2001, Steroids.

[28]  I. Lindley,et al.  Natural metabolites of 1α,25‐dihydroxyvitamin D3 retain biologic activity mediated through the vitamin D receptor , 2000 .

[29]  C. Carlberg,et al.  Vitamin D and cancer: effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. , 2001, Frontiers in bioscience : a journal and virtual library.

[30]  B. Boucher,et al.  METABOLISM OF INTRAVENOUSLY ADMINISTERED CHOLECALCIFEROL IN MAN , 1979, Clinical endocrinology.

[31]  R. Vieth,et al.  Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. , 1999, The American journal of clinical nutrition.

[32]  J. Padbury,et al.  1α,25-Dihydroxy-3-epi-vitamin D3, a natural metabolite of 1α,25-dihydroxy vitamin D3: production and biological activity studies in pulmonary alveolar type II cells , 2002 .

[33]  I. Schuster,et al.  1α,25-Dihydroxy-3-epi-vitamin D3 a physiological metabolite of 1α,25-dihydroxyvitamin D3: Its production and metabolism in primary human keratinocytes , 2000, Molecular and Cellular Endocrinology.

[34]  J. Eisman,et al.  Nonhypercalcemic 1,25‐(OH)2D3 analogs potently induce the human osteocalcin gene promoter stably transfected into rat osteosarcoma cells (ROSCO‐2) , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.